Clinical Trials Browser

Withdrawn × Capecitabine × Breast × Clear all

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01349088 2025-05-02

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05227131 2022-07-11

MARGARET

Phase 2 Withdrawn

Breast Neoplasms

NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase 2/3 Withdrawn

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00960544 2019-06-14

Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism

Phase 2 Withdrawn

Breast Neoplasms

NCT02915172 2017-06-26

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Phase 1 Withdrawn

BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

NCT01227408 2017-05-02

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT00450515 2016-12-06

Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Breast Neoplasms, Male

NCT00964704 2016-11-02

A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms